OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, today announced the pricing of its public offering of 6,500,000 shares of its common stock at $3.65 per share. The Company expects to complete the sale of these shares pursuant to its effective shelf registration statement on or about December 20, 2005. The Company has granted the underwriters a 30-day option to purchase 975,000 additional shares of its common stock to cover over-allotments, if any.
